Skip to content

Study · Animal study (in vivo) · mouse · 2020

5 results

Association of glucagon-like peptide-1 receptor-targeted imaging probe with in vivo glucagon-like peptide-1 receptor agonist glucose-lowering effects.

Murakami T, Fujimoto H, Fujita N, Hamamatsu K, Yabe D, Inagaki N

Journal of diabetes investigation1 Jun 2020Cited by 13 (Europe PMC)

PMID32323451 (opens in a new tab)PMCIDPMC7610126 (opens in a new tab)DOI10.1111/jdi.13281 (opens in a new tab)PepBankPUB-32323451
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice classified as dulaglutide non-responders, post-treatment non-fasting glucose averaged 330.8 mg/dL.

    In plain wordsIn mice classified as dulaglutide non-responders, blood sugar averaged 330.8 mg/dL after treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicablePost-treatment glucose in non-responders
    Study

    mousen = 5

    Diabetic NONcNZO10/LtJ male mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 3 weeksAs given in this study (mouse).

    Measurements

    Non-fasting glucose
    330.8 mg/dL
    non-responders

    Source sentences

    Summary
    The non-fasting blood glucose levels after treatment were 172.5 ± 42.4 mg/dL in responders (n = 4) and 330.8 ± 20.7 mg/dL in non-responders (n = 5), respectively.
    2 context sentences
    Summary · context
    Diabetic mice were selected from NONcNZO10/LtJ male mice that were fed for different durations with 11% fat chow.
    Summary · context
    After 3-week administration of dulaglutide as GLP-1RA therapy, mice with non-fasting blood glucose levels 300 mg/dL were defined as responders and non-responders, respectively.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice classified as dulaglutide responders, post-treatment non-fasting glucose averaged 172.5 mg/dL.

    In plain wordsIn mice classified as dulaglutide responders, blood sugar averaged 172.5 mg/dL after treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicablePost-treatment glucose in responders
    Study

    mousen = 4

    Diabetic NONcNZO10/LtJ male mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 3 weeksAs given in this study (mouse).

    Measurements

    Non-fasting glucose
    172.5 mg/dL
    responders

    Source sentences

    Summary
    The non-fasting blood glucose levels after treatment were 172.5 ± 42.4 mg/dL in responders (n = 4) and 330.8 ± 20.7 mg/dL in non-responders (n = 5), respectively.
    2 context sentences
    Summary · context
    Diabetic mice were selected from NONcNZO10/LtJ male mice that were fed for different durations with 11% fat chow.
    Summary · context
    After 3-week administration of dulaglutide as GLP-1RA therapy, mice with non-fasting blood glucose levels 300 mg/dL were defined as responders and non-responders, respectively.

Studies that did not test the peptide alone3

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 03AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Other

    In dulaglutide-treated diabetic mice, pancreatic imaging-probe accumulation correlated with post-treatment glycohemoglobin.

    In plain wordsIn mice given dulaglutide, pancreatic probe accumulation was linked to blood glycohemoglobin after treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableProbe association with post-treatment glycohemoglobin
    Study

    mousen: not reported in source

    Diabetic NONcNZO10/LtJ male mice
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    R squared
    0.76 ratio
    glycohemoglobin

    Source sentences

    Summary
    Ex vivo 111 In-Ex4 pancreatic values showed significant correlations with post-treatment glycohemoglobin and glucose area under curve during an oral glucose tolerance test (R2  = 0.76 and 0.80; P < 0.01 and <0.01, respectively).
    3 context sentences
    Summary · context
    We developed 111 Indium-labeled exendin-4 derivative (111 In-Ex4) as a GLP-1R-targeting probe.
    Summary · context
    Diabetic mice were selected from NONcNZO10/LtJ male mice that were fed for different durations with 11% fat chow.
    Summary · context
    After 3-week administration of dulaglutide as GLP-1RA therapy, mice with non-fasting blood glucose levels 300 mg/dL were defined as responders and non-responders, respectively.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 04AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Other

    In dulaglutide-treated diabetic mice, pancreatic imaging-probe accumulation correlated with glucose area under the curve during oral glucose testing.

    In plain wordsIn mice given dulaglutide, pancreatic probe accumulation was linked to blood sugar during glucose tolerance testing.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableProbe association with glucose tolerance AUC
    Study

    mousen: not reported in source

    Diabetic NONcNZO10/LtJ male mice
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    R squared
    0.8 ratio
    glucose AUC

    Source sentences

    Summary
    Ex vivo 111 In-Ex4 pancreatic values showed significant correlations with post-treatment glycohemoglobin and glucose area under curve during an oral glucose tolerance test (R2  = 0.76 and 0.80; P < 0.01 and <0.01, respectively).
    3 context sentences
    Summary · context
    We developed 111 Indium-labeled exendin-4 derivative (111 In-Ex4) as a GLP-1R-targeting probe.
    Summary · context
    Diabetic mice were selected from NONcNZO10/LtJ male mice that were fed for different durations with 11% fat chow.
    Summary · context
    After 3-week administration of dulaglutide as GLP-1RA therapy, mice with non-fasting blood glucose levels 300 mg/dL were defined as responders and non-responders, respectively.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 05AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Other

    In diabetic mice, pancreatic imaging-probe accumulation identified dulaglutide responders with a receiver operating characteristic area under the curve of 1.00.

    In plain wordsIn mice, pancreatic probe accumulation identified dulaglutide responders with a receiver operating characteristic area under the curve of 1.00.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableProbe discrimination of responders
    Study

    mousen: not reported in source

    Diabetic NONcNZO10/LtJ male mice
    Outcome group
    Diagnostic test performance · Metabolic and weight

    Source sentences

    Summary
    The receiver operating characteristic area under curve for identifying responders by ex vivo 111 In-Ex4 pancreatic values was 1.00 (P < 0.01).
    3 context sentences
    Summary · context
    We developed 111 Indium-labeled exendin-4 derivative (111 In-Ex4) as a GLP-1R-targeting probe.
    Summary · context
    Diabetic mice were selected from NONcNZO10/LtJ male mice that were fed for different durations with 11% fat chow.
    Summary · context
    After 3-week administration of dulaglutide as GLP-1RA therapy, mice with non-fasting blood glucose levels 300 mg/dL were defined as responders and non-responders, respectively.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.